LARVOL Blog | SITC22 Reactions

Back to Blog

Abstract #O789: AmodSarnaik presented pooled efficacy and safety data from two cohorts of the P2 C-144–01 trial in progress, assessing lifileucel in 153 heavily pre-treated patients with advanced melanoma after progression on ICI.

Results: Lifileucel demonstrated a *31% ORR**. Median* DOR not reached at *36.5 months**, with 41.7%of responses maintained at ≥24 months.* 79.3% of patients had a reduction in tumor burden. Safety profile consistent with that of NMA-LDand IL-2.

‍

‍

Thought leader reactions were positive, with several experts saying that TIL should get accelerated approval for use in this difficult to treat population, as it provided meaningful clinical benefit with reasonable safety.

‍

‍

Of particular interest was the durability of response to lifileucel.

‍

‍

Summary: This analysis of patients treated with lifileucel represents a positive step for heavily-pretreated, advanced melanoma patients, a population with limited treatment options. Thought leaders feel that TIL therapies should be approved in this population, as durable and appreciable efficacy was achieved with no serious safety concerns.

‍

Synthesis by Opus Strategy, LLC

Download attached file

Not rated

Allison Betof Warner, MD, PhD (she/her) 4

@DrBetofMDPhD

3743

Manhattan, NY

November 10, 2022

79% had reduction in disease. ORR 31%. Many responses deepen over time.

Not rated

Allison Betof Warner, MD, PhD (she/her) 3

@DrBetofMDPhD

3743

Manhattan, NY

November 10, 2022

Median DOR not yet reached. Median OS 13.9 mo. 12 mo OS was 54%. As typical with immunotherapy, we see a nice tail on the curve. #TIL #SITC22

Positive

Alex Shoushtari, MD

@alexshoushtari

2253

New York, USA

November 10, 2022

Important work on efficacy of TIL therapy lifileucel in PD-1 resistant #melanoma being presented at #SITC22. Pretty good durability for this heavy lift of a treatment.

Not rated

Allison Betof Warner, MD, PhD (she/her) 2

@DrBetofMDPhD

3743

Manhattan, NY

November 10, 2022

Toxicity profile was in line with prior TIL/Lifileucel data. No surprises here. Median # doses of IL-2 was 6.

Positive

Hussein Tawbi, MD, PhD

@HTawbi_MD

1685

Houston, TX

November 10, 2022

Absolutely agree!… this should be available to our melanoma patients ASAP!… and paves the way for smarter cellular therapies to be designed, studied, and eventually widely disseminated

Positive

Allison Betof Warner, MD, PhD (she/her) 1

DrBetofMDPhD

3744

Manhattan, NY

November 10, 2022

Where does this leave us with #TIL therapy for #melanoma? IMO, this response rate/durability justifies accelerated approval. Pts with PD-1 refractory melanoma need options. It’s FAR from a perfect tx but provides meaningful clinical benefit. What say you melanoma Twitterverse?

Not Rated

Sumanta K. Pal, MD, FASCO

@montypal

15083 Followers

Los Angeles, CA

November 8, 2022

Just before I start AM clinic at @cityofhopeoc, excited to share results from #COBALT_RCC, a P1 trial of @CRISPRTX #CTX130 in #kidneycancer in the @sitcancer #PressProgram. Will present more on Thurs 5:37p at #SITC22! Thx @neerajaiims @DrBenTran @HaanenJohn #SamerSrour& co-Is! t.co/aDnhG9n92A

not rated

Shilpa Gupta

@Shilpaonc

5095 Followers

Cleveland, OH

November 8, 2022

@montypal @cityofhopeoc @CRISPRTX @sitcancer @neerajaiims @DrBenTran @HaanenJohn @DrChoueiri @TiansterZhang @tompowles1 @brian_rini @AlbigesL @Uromigos @ERPlimackMD @drenriquegrande @PGrivasMDPhD Congrats Monty! Looking forward to hearing about this exciting first-in the field study!

Not Rated

Tian Zhang, MD, MHS

@TiansterZhang

6463 Followers

Dallas, TX

November 8, 2022

CAR-Ts are coming for #kidneycancer!! Congratulations @montypal and team; can’t wait to see results at #SITC22! t.co/9MrlF2yzBe

Not Rated

Moshe Ornstein MD

@MosheOrnsteinMD

1930 Followers

Cleveland, OH

November 8, 2022

Congrats @montypal and team! Great to see CAR T therapy coming to #RCC t.co/ypRHBC89Pt

Not Rated

Shuchi Gulati MD

@ShuchiGulati

12476 Followers

Seattle, WA

November 8, 2022

Another huge step from none other than @montypal!! CAR-Ts in #kidneycancer!Congratulations to the entire team!Looking forward to seeing the results at #SITC22! t.co/HvKeVBPyV7

Not Rated

Petros Grivas

@PGrivasMDPhD

12476 Followers

Seattle, WA

November 8, 2022

@montypal you never stop to amaze me! You are brilliant & awesome! Looking forward to hearing more about this trial @sitcancer @OncoAlert @CityofHope_GU @COHMDCareers @neerajaiims @KidneyCancer @KidneyCancerDoc @NazliDizman @ZeynepZengin @LuisMezaco @crisbergerot @PauloBergerot t.co/RNzOwxixQm

SITC22 Reactions - Lifileucel

SITC22 Reactions - Lifileucel

Abstract #O789: AmodSarnaik presented pooled efficacy and safety data from two cohorts of the P2 C-144–01 trial in progress, assessing lifileucel in 153 heavily pre-treated patients with advanced melanoma after progression on ICI.

Results: Lifileucel demonstrated a *31% ORR**. Median* DOR not reached at *36.5 months**, with 41.7%of responses maintained at ≥24 months.* 79.3% of patients had a reduction in tumor burden. Safety profile consistent with that of NMA-LDand IL-2.

Thought leader reactions were positive, with several experts saying that TIL should get accelerated approval for use in this difficult to treat population, as it provided meaningful clinical benefit with reasonable safety.

Of particular interest was the durability of response to lifileucel.

Subscribe to our newsletter

Sign up for our newsletter to get the latest news, updates and high-impact data delivered directly to your inbox.

From Passion to Profession: Meet LARVOL’s VP Sales, Linh Nguyen

Our Shift to the Metaverse: A Conversation with CEO Bruno Larvol

The Latest in ADCs: Precision Tools in Cancer Treatment

LARVOL's CONF Case Study: An In-depth Q&A with Angela Kaya, Director of Publications & Scientific Communications at PMV Pharma

Solutions

Services

Insights

Company

Contact

SITC22 Reactions - Lifileucel

SITC22 Reactions - Lifileucel

Abstract #O789: Amod Sarnaik presented pooled efficacy and safety data from two cohorts of the P2 C-144–01 trial in progress, assessing lifileucel in 153 heavily pre-treated patients with advanced melanoma after progression on ICI.

Results: Lifileucel demonstrated a 31% ORR. Median DOR not reached at 36.5 months, with 41.7%of responses maintained at ≥24 months. 79.3% of patients had a reduction in tumor burden. Safety profile consistent with that of NMA-LDand IL-2.

Thought leader reactions were positive, with several experts saying that TIL should get accelerated approval for use in this difficult to treat population, as it provided meaningful clinical benefit with reasonable safety.

Of particular interest was the durability of response to lifileucel.

Subscribe to our newsletter

Sign up for our newsletter to get the latest news, updates and high-impact data delivered directly to your inbox.

From Passion to Profession: Meet LARVOL’s VP Sales, Linh Nguyen

Our Shift to the Metaverse: A Conversation with CEO Bruno Larvol

The Latest in ADCs: Precision Tools in Cancer Treatment

LARVOL's CONF Case Study: An In-depth Q&A with Angela Kaya, Director of Publications & Scientific Communications at PMV Pharma

Solutions

Services

Insights

Company

Contact

Abstract #O789: AmodSarnaik presented pooled efficacy and safety data from two cohorts of the P2 C-144–01 trial in progress, assessing lifileucel in 153 heavily pre-treated patients with advanced melanoma after progression on ICI.

Results: Lifileucel demonstrated a *31% ORR**. Median* DOR not reached at *36.5 months**, with 41.7%of responses maintained at ≥24 months.* 79.3% of patients had a reduction in tumor burden. Safety profile consistent with that of NMA-LDand IL-2.